Document is current
Any future updates will be listed below
-
Authors
Piuzzi, Nicolas
Yost, Larry
Putnam, William
Springer, Bryan
de Beaubien, Brian
Urish, Kenneth
Parvizi, Javad
-
Funding
Funding for this research was provided by:
Osteal Therapeutics
- License Information
-
More Information
Article History
Received: 18 March 2025
Accepted: 1 June 2025
First Online: 23 June 2025
Declarations
:
: Nicolas Piuzzi has received research grants from with Osteal Therapeutics, RegenLab, Zimmer, Peptilogics, and Signature Orthopaedics; is a board or committee member of AAHKS, ISCT, ORS; is on the editorial board or governing board of Journal of Hip Surgery, Journal of Knee Surgery; is a consultant for Zimmer-Biomet. Larry Yost reports receiving payment from Osteal Therapeutics for conducting the systematic literature reported in this paper and medical writing services associated with the preparation of this manuscript. William Putnam reports being an employee of Osteal Therapeutics. Brian de Beaubien report receiving royalties from Link Orthopedics and MicroPort Orthopedics; has received research grants from MicroPort Orthopedics; and is a paid consultant and has stock options with Osteal Therapeutics. Kennth Urish reports being a paid consultant for Smith & Nephew, Peptilogics, Osteal Therapeutics, Adaptive Phage Therapeutics, and BiomX; and has stock options with Peptilogics and Osteal Therapeutics. Javad Parvizi reports receiving research support from the NIH, the Department of Defense, OREF, 3 M, Aesculap, AO Spine, Biomet, Cempra, CeramTec, DePuy, Integra, Lima, Myoscience, NDRI, Novartis, Pfizer, Rotation Medical, Simplify Medical, Smith and Nephew, Stelkast, Stryker Orthopedics, Synthes, TissueGene, Tornier, Orthospace, Zimmer Biomet, has received royalties from Becton Dickenson, Corentec, Datatrace, Elsevier, Jaypee publishers, Slack, Wolters Kluwer; being a paid consultant for Becton Dickinson, Corentec, Convatec, Cardinal Health, Ethicon, G-21, KCI / 3 M (Acelity), Osteal Therapeutics, and Zimmer Biomet; and has equity ownership with Acumed, Alphaeon/Strathsby Crown, Ceribell, Coracoid, Corin, Efferent, Elute, Hip Innovation Technology, Illuminos, Intellijoint, Molecular Surface Tech., Nanooxygenic, Optinutrium, Osteal, Parvizi Surgical Innovation and subsidiaries, Peptilogic, Plasmology4, Sonata, Sonogen, and Tangen.
